Previous Article | Next Article ![]()
Mol. Cell. Biol., 01 1995, 290-297, Vol 15, No. 1
JA Vilpo, LM Vilpo, DE Szymkowski, A O'Donovan and RD Wood
One of the most widely used antitumor drugs is cis-
diamminedichloroplatinum(II) (cisplatin), and mechanisms of cisplatin
resistance have been investigated in numerous model systems. Many studies
have used mouse leukemia L1210/0 as a reference wild-type cell line, and
cisplatin-resistant subclones have been derived from it. Increased DNA
excision repair capacity is thought to play a key role in the acquired
cisplatin resistance, and this has influenced development of drugs for
clinical trials. We report here that the L1210/0 line is in fact severely
deficient in nucleotide excision repair of damaged DNA in vivo and in
vitro. L1210/0 cell extracts could be complemented by extracts from
repair-defective human xeroderma pigmentosum (XP) or rodent excision repair
cross-complementing (ERCC) mutant cells, except for XPG/ERCC5 mutants.
Purified XPG protein could restore repair proficiency to L1210/0 extracts.
Expression of mouse XPG mRNA was similar in all L1210 lines studied,
suggesting a point mutation or small alteration of XPG in L1210/0 cells.
The DNA repair capacity of a cisplatin-resistant subline, L1210/DDP10, is
similar to that of type culture collection L1210 cells and to those of
other normal mammalian cell lines. Nucleotide excision repair of DNA is
thus clearly important in the intrinsic cellular defense against cisplatin.
However, in contrast to what is generally believed, enhancement of DNA
repair above the normal level in these rodent cells does not appear to be a
mechanism of acquired resistance to the drug.
Copyright © 1995, American Society for Microbiology
An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells
Imperial Cancer Research Fund, Clare Hall Laboratories, South Mimms, Hertfordshire, United Kingdom.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|